vimarsana.com

Page 6 - மருத்துவ ஆராய்ச்சி தேசிய நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DGCI gives nod for Covaxin Phase II/III trials on 2-18 year olds | India News

Ocugen Provides Business Update and First Quarter 2021 Financial Results

and Variant Neutralization Results In April 2021, Ocugen announced that its co-development partner, Bharat Biotech International Limited ( Bharat Biotech ), shared positive results from the second interim analysis of its Phase 3 clinical trial of COVAXIN showing 78% overall efficacy against COVID-19 disease, 100% efficacy against severe COVID-19 disease (including hospitalization), and 70% efficacy against asymptomatic COVID-19 infection, indicating the potential to significantly reduce virus transmission. COVAXIN has additionally demonstrated a remarkable safety profile with several million doses administered to date in India. Moreover, in-vitro studies conducted by the Indian Council of Medical Research-National Institute of Virology have provided data suggesting effectiveness in neutralizing the double mutant India variant, the U.K. variant, and the Brazil variant. Based on broad immunogenicity, Ocugen believes that COVAXIN has the potential to be effective against other emergi

India s COVID-19 Vaccine Found Effective Against Brazil and UK Variants

May 2, 2021 • 4:02 pm CDT (Precision Vaccinations) Scientists at the Indian Council of Medical Research-National Institute of Virology confirmed on April 30, 2021, they have found that the Covaxin COVID-19 vaccine is effective against the Brazil variant, B.1.128.2. Published as a bioRxiv preprint, this new study shows that the two-dose regimen significantly boosted IgG antibody titer and neutralizing efficacy against the Brazil variant and D614G variant as compared to that seen with natural infection. This study also demonstrated 1.92 and 1.09 fold reductions in the neutralizing titer against B.1.1.28.2 variant compared to prototype D614G variant with sera of vaccine recipients and natural infection, respectively.

Coronavirus: Kent variant is surging in India as cases spike in second wave crisis

Is the Kent Covid variant fuelling India s explosion in infections? Cases of mutant strain in Kerala region have risen 10-FOLD in a month and now make up a THIRD of all samples… and it is linked to 90% of positives in northern states Kent Covid variant already dominant in the UK and US and it is in 130 countries Indian reports show it accounts for surging proportion of infections there It is known to be faster-spreading than other strains of the virus Not much is known about the Indian variant but it doesn t appear to be worse India is in a state of crisis with hospitals overwhelmed and thousands dying 

Ocugen Partner Reports Strong Phase 3 Results for Coronavirus Vaccine

Author Bio Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles. A new coronavirus vaccine candidate could soon be authorized for use, if its excellent clinical results are any indication. Ocugen (NASDAQ:OCGN) has unveiled the results of a phase 3 clinical trial of the Covaxin vaccine conducted by its co-development partner Bharat Biotech. Most notably, the vaccine demonstrated 100% efficacy against severe COVID-19.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.